Quantum BioPharma Ltd. (QNTM) News
Track canonical SquawkNews coverage tagged to QNTM, Quantum BioPharma Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Quantum BioPharma Ltd. (QNTM) Licensee Unbuzzd Names Michael Zapolin CEO
Quantum BioPharma said its licensee Unbuzzd Wellness appointed Michael “Zappy” Zapolin as CEO, with a mandate to seek financing, pursue a stock exchange listing, and lead a U.S. rollout.Material DetailsContext by AI Anal
EQUITY | Sep 24, 2026, 12:03 PM UTC
L
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. NASDAQ:QNTM FRA:0K91 (“Quantum BioPharma”), today announced its licensee — Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd
NEWS | Sep 24, 2026, 12:03 PM UTC
L
QNTM - Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
QNTM - Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
NEWS | Sep 17, 2026, 12:00 PM UTC
L
QNTM - Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
QNTM - Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
NEWS | Sep 15, 2026, 12:01 PM UTC
L
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Toronto, Ontario--(. - September 15, 2026) - Quantum BioPharma Ltd. NASDAQ:QNTM (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and b
NEWS | Sep 15, 2026, 12:01 PM UTC
L
QNTM receives FDA clearance to begin MS treatment trials
Quantum BioPharma Ltd. (NASDAQ: QNTM) received FDA clearance to begin trials for its MS treatment.
REGULATION | Sep 09, 2026, 12:30 PM UTC
L
Quantum Biopharma plans voluntary delisting of Class B shares in Canada
Quantum Biopharma said it plans to voluntarily delist its Class B shares from the Canadian Securities Exchange.
EQUITY | Sep 01, 2026, 11:02 PM UTC
L
Quantum BioPharma initiated at Buy by Rodman & Renshaw
Rodman & Renshaw initiated coverage on Quantum BioPharma with a Buy rating.
EQUITY | Aug 31, 2026, 05:11 PM UTC
M
QNTM equity, liquidity strengthened as FDA approves Lucid-MS trial
Quantum BioPharma says it strengthens equity and liquidity in Q2 2026 following FDA approval of Lucid-MS for a pivotal Phase 2 clinical trial.
EQUITY | Aug 14, 2026, 11:00 AM UTC
M
QNTM Advances MS Therapy
Quantum BioPharma Ltd. is advancing an innovative, first-in-class, patented MS therapy
EQUITY | Jun 25, 2026, 12:30 PM UTC
M
QNTM Developing MS Treatment
Quantum BioPharma Ltd. is developing a patented, first-in-class MS treatment that offers a different approach
EQUITY | Jun 23, 2026, 12:31 PM UTC